{diabetes}

Current Speaker Experts: Peng Xiaolan, women, First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital) Department of Endocrinology, deputy director of the physicians, engaged in clinical care, teaching and research for 20 years, specializes in treatment of diabetes, thyroid disease, adrenal disease, pituitary disease and so on. Clinic hours: Tuesday afternoon, Thursday morning, Sunday morning. [Details]
Expert Lecture: Treatment of diabetes with oral hypoglycemic agents

Peng Xiaolan explained to the patient's knowledge of oral hypoglycemic agents

Introduction: Type 2 diabetes is a progressive disease

The so-called advanced disease, which means that it will become increasingly important. Progression of diabetes and the treatment can be summarized in three stages:

1, when the diabetes less often, the islet B cell function in the time remaining, when controlled through diet and exercise to control the disease;

2, if the diabetes does not control when the light is good, islet B cell function will be gradually reduced, this time the need to diet and exercise on the basis of treatment with oral hypoglycemic agents;

3, and then allowed to develop diabetes, islet B cell function is worsening and even tended to failure, this time, we must use insulin therapy to control blood sugar was.
Expert Lecture: Treatment of diabetes with oral hypoglycemic agents

Type 2 diabetes is a progressive disease

Because diabetes is a progressive disease, so to remind you, its not safe to assume the psychological: that their blood glucose to normal after medication, the patient is like, and you do not need the medication. In fact, is not the case, the disease will become increasingly serious.

Treatment of diabetes with oral hypoglycemic agents

◆ indication for oral hypoglycemic agents

1, for the treatment of type 2 diabetes - through diet control and exercise therapy, glycemic control were still not satisfied;

2, for type 1 diabetes - insulin therapy at the same time in some combination of oral hypoglycemic agents and, in fact, clinical type 1 diabetes is rarely used oral hypoglycemic drugs;

3, for type 2 diabetes - under certain circumstances (eg, combined with pneumonia, trauma, infarction, or need surgery, myocardial infarction event, etc.) should adopt the insulin treatment;

◆ classification of oral hypoglycemic agents

Insulin secretion agents - sulfonylureas: If glibenclamide; non-sulfonylurea (nateglinide class): If nateglinide, repaglinide.

Insulin sensitizers (glitazones) - such as: rosiglitazone, pioglitazone;

To promote glucose utilization (metformin) - such as: Metformin;

Inhibition of intestinal glucose absorption (acarbose) - such as: Acarbose (Acarbose), voglibose;

The first agent on insulin secretion

The first generation of sulfonylureas - a small urea sulfur, chlorine sulfur C urea

Second-generation sulfonylureas -

- Glibenclamide (glibenclamide) (Xiaoke Pill)

- Gliclazide (Diamicron) (gliclazide sustained-release tablets)

- Glipizide (glipizide) (glipizide)

- Gliquidone (Gliquidon)